Fate Therapeutics Inc (FATE)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
J. Scott Wolchko
Employees:
450
3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO, CA 92121
858.875.1803

Fate Therapeutics, Inc. develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cells product candidates.

Data derived from most recent annual or quarterly report
Market Cap 3.155 Billion Shares Outstanding96.629 Million Avg 30-day Volume 1.341 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.45
Price to Revenue35.1086 Debt to Equity0.1836 EBITDA-239.045 Million
Price to Book Value4.1282 Operating Margin-412.5427 Enterprise Value1.922 Billion
Current Ratio6.547 EPS Growth-0.118 Quick Ratio6.359
1 Yr BETA 2.0511 52-week High/Low 92.7 / 17.1 Profit Margin-371.7295
Operating Cash Flow Growth-100.2188 Altman Z-Score4.5604 Free Cash Flow to Firm -291.023 Million
Earnings Report2022-11-03
View SEC Filings from FATE instead.

View recent insider trading info

Funds Holding FATE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding FATE

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-08-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-30:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-13:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-02-28:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-12-14:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-04:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 1.02: Termination of a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-08-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-08-04:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    65 Thousand total shares from 8 transactions

    Exercise Derivative Conversion (M)

    61.2 Thousand total shares from 5 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    WOLCHKO J SCOTT PRESIDENT AND CEO

    • Officer
    • Director
    869,338 2022-07-21 10

    VALAMEHR BAHRAM CHIEF R&D OFFICER

    • Officer
    192,990 2022-07-07 9

    PLAVSIC MARK CHIEF TECHNICAL OFFICER

    • Officer
    127,123 2022-07-05 3

    POWL BRIAN T. CHIEF COMMERCIAL OFFICER

    • Officer
    115,000 2022-06-27 2

    RASTETTER WILLIAM H

    • Director
    629,317 2022-06-09 1

    MENDLEIN JOHN

    • Director
    178,634 2022-06-09 3

    HERSHBERG ROBERT

    • Director
    22,552 2022-06-09 2

    COUGHLIN TIMOTHY

    • Director
    78,175 2022-06-09 2

    REDMILE GROUP, LLC

    GREEN JEREMY

    • Director
    • 10% Owner
    12,980,446 2022-06-09 1

    AGARWAL SHEFALI

    • Director
    22,383 2022-06-09 4

    LEE MICHAEL STEWART

    • Director
    23,224 2022-06-09 1

    JOOSS KARIN

    • Director
    21,741 2022-06-09 2

    XU YUAN

    • Director
    25,287 2022-06-09 1

    TAHL CINDY GENERAL COUNSEL AND SECRETARY

    • Officer
    243,361 2022-06-01 6

    CHU YU-WAYE CHIEF MEDICAL OFFICER

    • Officer
    151,033 2022-04-19 5

    DULAC EDWARD J III CHIEF FINANCIAL OFFICER

    • Officer
    194,994 2022-01-25 6

    EPSTEIN ROBERT S

    • Director
    23,224 2021-06-09 0

    SHOEMAKER DANIEL D CHIEF SCIENTIFIC OFFICER

    • Officer
    73,020 2021-03-08 0

    NASHAT AMIR

    • Director
    2,310,432 2019-07-31 0

    ABBOT STEWART CHIEF DEVELOPMENT OFFICER

    • Officer
    64,917 2018-05-15 0

    STORGARD CHRIS CHIEF MEDICAL OFFICER

    • Officer
    0 2018-01-16 0

    ENYEDY MARK J

    • Director
    0 2017-05-02 0

    FATE THERAPEUTICS INC CHIEF SCIENTIFIC OFFICER

    • Officer
    103,816 2016-01-08 0

    WEYER CHRISTIAN SEE REMARKS

    • Officer
    • Director
    30,429 2015-04-13 0

    MULTANI PRATIK S CHIEF MEDICAL OFFICER

    • Officer
    3,024 2015-01-05 0

    FLYNN PETER D SEE REMARKS

    • Officer
    6,505 2015-01-05 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    WOLCHKO J SCOTT - Director - Officer PRESIDENT AND CEO

    2022-07-25 18:18:08 -0400 2022-07-22 M 6,246 d 0 direct yes

    WOLCHKO J SCOTT - Director - Officer PRESIDENT AND CEO

    2022-07-25 18:18:08 -0400 2022-07-22 S 620 $33.28 d 431,546 direct yes 5.7043 -2.3901 5.7043 2 -4.2702 5

    WOLCHKO J SCOTT - Director - Officer PRESIDENT AND CEO

    2022-07-25 18:18:08 -0400 2022-07-22 S 2,703 $32.61 d 432,166 direct yes 5.7043 -2.3901 5.7043 2 -4.2702 5

    WOLCHKO J SCOTT - Director - Officer PRESIDENT AND CEO

    2022-07-25 18:18:08 -0400 2022-07-22 S 2,923 $31.33 d 434,869 direct yes 5.7043 -2.3901 5.7043 2 -4.2702 5

    WOLCHKO J SCOTT - Director - Officer PRESIDENT AND CEO

    2022-07-25 18:18:08 -0400 2022-07-22 M 6,246 $2.70 a 437,792 direct yes 5.7043 -2.3901 5.7043 2 -4.2702 5

    WOLCHKO J SCOTT - Director - Officer PRESIDENT AND CEO

    2022-07-25 18:18:08 -0400 2022-07-21 M 30,000 d 6,246 direct yes

    WOLCHKO J SCOTT - Director - Officer PRESIDENT AND CEO

    2022-07-25 18:18:08 -0400 2022-07-21 S 19,171 $33.07 d 431,546 direct yes 5.7043 -2.3901 5.7043 2 -4.2702 5

    WOLCHKO J SCOTT - Director - Officer PRESIDENT AND CEO

    2022-07-25 18:18:08 -0400 2022-07-21 S 10,829 $32.54 d 450,717 direct yes 5.7043 -2.3901 5.7043 2 -4.2702 5

    WOLCHKO J SCOTT - Director - Officer PRESIDENT AND CEO

    2022-07-25 18:18:08 -0400 2022-07-21 M 30,000 $2.70 a 461,546 direct yes 5.7043 -2.3901 5.7043 2 -4.2702 5

    VALAMEHR BAHRAM - Officer CHIEF R&D OFFICER

    2022-07-08 16:51:04 -0400 2022-07-07 M 17,158 $2.73 d 13,156 direct yes

    VALAMEHR BAHRAM - Officer CHIEF R&D OFFICER

    2022-07-08 16:51:04 -0400 2022-07-07 S 17,158 $30.23 d 179,834 direct yes 4.4546 7.6114 11.1891 5 0.0 1

    VALAMEHR BAHRAM - Officer CHIEF R&D OFFICER

    2022-07-08 16:51:04 -0400 2022-07-07 M 17,158 $2.73 a 196,992 direct yes 4.4546 7.6114 11.1891 5 0.0 1

    VALAMEHR BAHRAM - Officer CHIEF R&D OFFICER

    2022-07-07 16:04:11 -0400 2022-07-06 M 5,842 $2.73 d 30,314 direct yes

    VALAMEHR BAHRAM - Officer CHIEF R&D OFFICER

    2022-07-07 16:04:11 -0400 2022-07-06 M 2,000 $4.84 d 8,704 direct yes

    VALAMEHR BAHRAM - Officer CHIEF R&D OFFICER

    2022-07-07 16:04:11 -0400 2022-07-06 S 7,842 $30.07 d 179,834 direct yes -4.9983 5.6315 5.6315 6 -4.9983 2

    VALAMEHR BAHRAM - Officer CHIEF R&D OFFICER

    2022-07-07 16:04:11 -0400 2022-07-06 M 5,842 $2.73 a 187,676 direct yes -4.9983 5.6315 5.6315 6 -4.9983 2

    VALAMEHR BAHRAM - Officer CHIEF R&D OFFICER

    2022-07-07 16:04:11 -0400 2022-07-06 M 2,000 $4.84 a 181,834 direct yes -4.9983 5.6315 5.6315 6 -4.9983 2

    PLAVSIC MARK - Officer CHIEF TECHNICAL OFFICER

    2022-07-06 16:04:56 -0400 2022-07-05 S 3,719 $24.61 d 127,123 direct -2.9745 1.8752 1.8752 6 -7.8241 3

    POWL BRIAN T. - Officer CHIEF COMMERCIAL OFFICER

    2022-06-29 17:02:35 -0400 2022-06-27 A 45,000 a 45,000 direct 1.4528 21.1057 36.481 37.7724 27 0.0 1

    POWL BRIAN T. - Officer CHIEF COMMERCIAL OFFICER

    2022-06-29 17:02:35 -0400 2022-06-27 A 70,000 a 70,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    FATE THERAPEUTICS INC FATE 2022-08-12 22:15:03 UTC 2.0234 0.2966 850000
    FATE THERAPEUTICS INC FATE 2022-08-12 21:45:04 UTC 2.0234 0.2966 850000
    FATE THERAPEUTICS INC FATE 2022-08-12 21:15:04 UTC 2.0234 0.2966 850000
    FATE THERAPEUTICS INC FATE 2022-08-12 20:45:04 UTC 2.0117 0.3083 850000
    FATE THERAPEUTICS INC FATE 2022-08-12 20:15:05 UTC 2.0117 0.3083 850000
    FATE THERAPEUTICS INC FATE 2022-08-12 19:45:03 UTC 2.0117 0.3083 850000
    FATE THERAPEUTICS INC FATE 2022-08-12 19:15:05 UTC 2.0117 0.3083 850000
    FATE THERAPEUTICS INC FATE 2022-08-12 18:45:03 UTC 2.013 0.307 850000
    FATE THERAPEUTICS INC FATE 2022-08-12 18:15:04 UTC 2.013 0.307 850000
    FATE THERAPEUTICS INC FATE 2022-08-12 17:45:04 UTC 2.013 0.307 850000
    FATE THERAPEUTICS INC FATE 2022-08-12 17:15:05 UTC 2.013 0.307 850000
    FATE THERAPEUTICS INC FATE 2022-08-12 16:45:04 UTC 2.0088 0.3112 850000
    FATE THERAPEUTICS INC FATE 2022-08-12 16:15:04 UTC 2.0088 0.3112 850000
    FATE THERAPEUTICS INC FATE 2022-08-12 15:45:04 UTC 2.0088 0.3112 800000
    FATE THERAPEUTICS INC FATE 2022-08-12 15:15:05 UTC 2.0088 0.3112 800000
    FATE THERAPEUTICS INC FATE 2022-08-12 14:45:04 UTC 2.0088 0.3112 850000
    FATE THERAPEUTICS INC FATE 2022-08-12 14:15:05 UTC 2.0088 0.3112 850000
    FATE THERAPEUTICS INC FATE 2022-08-12 13:45:04 UTC 2.0443 0.2757 850000
    FATE THERAPEUTICS INC FATE 2022-08-12 13:15:04 UTC 2.0443 0.2757 850000
    FATE THERAPEUTICS INC FATE 2022-08-12 12:45:04 UTC 2.0443 0.2757 800000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Trust for Professional Managers- Convergence Market Neutral Fund FATE -1793.0 shares, $-65265.2 2020-08-31 N-PORT
    FundVantage Trust- Gotham Defensive Long Fund FATE -75.0 shares, $-1665.75 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund FATE -22.0 shares, $-488.62 2020-03-31 N-PORT
    RUSSELL INVESTMENT CO- U.S. Dynamic Equity Fund FATE -972.0 shares, $-88092.36 2021-01-31 N-PORT
    Trust for Professional Managers- Convergence Long/Short Equity Fund FATE -1091.0 shares, $-60015.91 2021-11-30 N-PORT
    FundVantage Trust- Gotham Hedged Plus Fund FATE -89.0 shares, $-3450.53 2022-03-31 N-PORT
    RUSSELL INVESTMENT FUNDS- U.S. Small Cap Equity Fund FATE -1843.0 shares, $-71453.11 2022-03-31 N-PORT
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund FATE -100.0 shares, $-3877.0 2022-03-31 N-PORT
    Trust for Professional Managers- Convergence Long/Short Equity ETF FATE -2037.0 shares, $-47054.7 2022-05-31 N-PORT
    RUSSELL INVESTMENT CO- Sustainable Equity Fund FATE -2967.0 shares, $-84737.52 2022-04-30 N-PORT
    RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund FATE -10193.0 shares, $-291112.08 2022-04-30 N-PORT

    Elevate your investments